By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



4550 Towne Centre Court

San Diego  California  92121  U.S.A.
Phone: 858-558-7500 Fax: 858-552-8775

Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.

Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), small-cell lung and prostate cancer.

As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.

Key Statistics

Ownership: Subsidiary

Web Site: Celgene (San Diego)
Employees: 2,000 worldwide
Symbol: CELG



Novartis Corporation  Discovery and Development of Selective estrogen receptor modulators for the treatment of osteoporosis

Novartis Corporation  Commercialization of FocalinTM for ADHD

Company News
Bristol-Myers Squibb Company (BMY) And Celgene (CELG) Enter Clinical Collaboration Agreement To Evaluate Immunotherapy And Chemotherapy Combination Regimen 8/20/2014 8:25:44 AM
Celgene (CELG) Reports Second Quarter 2014 Operating and Financial Results 7/24/2014 11:36:44 AM
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/24/2014 6:34:56 AM
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/9/2014 7:18:47 AM
Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits In DMARD-Na├»ve Patients With Active Psoriatic Arthritis 6/11/2014 8:37:05 AM
Celgene (CELG) Release: Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits In Patients With Active Psoriatic Arthritis 6/11/2014 8:06:37 AM
Celgene (CELG) Release: Post-Hoc Analysis Of Overall Survival In Phase III MPACT Study Of Patients With Advanced Pancreatic Cancer Presented At American Society of Clinical Oncology 2014 6/2/2014 9:23:40 AM
Organization Changes At Celgene (CELG) Have Got Investors Wondering Who Will Take Over Once Hugin Steps Down 5/22/2014 9:14:50 AM
Celgene (CELG) Announces Presentations Of Investigational Studies In Solid Tumor And Blood Cancers At American Society of Clinical Oncology 2014 5/15/2014 8:11:26 AM
Celgene Corporation (CELG) Prices $2.5 Billion Of Senior Unsecured Notes 5/7/2014 6:45:37 AM